Zoetis Inc (NYSE:ZTS) Stock Position Lifted by Coastline Trust Co

Coastline Trust Co lifted its stake in shares of Zoetis Inc (NYSE:ZTS) by 12.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,346 shares of the company’s stock after purchasing an additional 2,581 shares during the quarter. Coastline Trust Co’s holdings in Zoetis were worth $2,909,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the company. Bath Savings Trust Co lifted its position in shares of Zoetis by 26.0% during the 2nd quarter. Bath Savings Trust Co now owns 7,293 shares of the company’s stock valued at $828,000 after buying an additional 1,505 shares in the last quarter. Park National Corp OH lifted its position in shares of Zoetis by 4.0% during the 2nd quarter. Park National Corp OH now owns 110,650 shares of the company’s stock valued at $12,558,000 after buying an additional 4,271 shares in the last quarter. Private Trust Co. NA lifted its position in shares of Zoetis by 3.7% during the 2nd quarter. Private Trust Co. NA now owns 15,519 shares of the company’s stock valued at $1,761,000 after buying an additional 556 shares in the last quarter. Dorsey Wright & Associates lifted its position in shares of Zoetis by 7.6% during the 2nd quarter. Dorsey Wright & Associates now owns 4,593 shares of the company’s stock valued at $521,000 after buying an additional 324 shares in the last quarter. Finally, WINTON GROUP Ltd lifted its position in shares of Zoetis by 2.3% during the 2nd quarter. WINTON GROUP Ltd now owns 7,534 shares of the company’s stock valued at $855,000 after buying an additional 171 shares in the last quarter. Institutional investors and hedge funds own 90.11% of the company’s stock.

In other Zoetis news, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $125.99, for a total value of $562,293.37. Following the completion of the sale, the executive vice president now directly owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $123.22, for a total value of $1,417,030.00. Following the completion of the sale, the executive vice president now directly owns 48,877 shares of the company’s stock, valued at $6,022,623.94. The disclosure for this sale can be found here. Insiders sold a total of 34,332 shares of company stock valued at $4,258,182 over the last ninety days. Corporate insiders own 0.29% of the company’s stock.

A number of research analysts have recently issued reports on the company. Credit Suisse Group set a $138.00 target price on Zoetis and gave the company a “buy” rating in a research report on Friday, October 11th. Argus set a $140.00 target price on Zoetis and gave the company a “buy” rating in a research report on Wednesday, September 4th. Craig Hallum increased their target price on Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Barclays increased their target price on Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley increased their price objective on Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a research note on Monday, September 30th. Eight research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Zoetis has an average rating of “Buy” and a consensus target price of $123.69.

NYSE ZTS opened at $128.12 on Friday. The business has a fifty day moving average price of $125.65 and a 200 day moving average price of $114.02. Zoetis Inc has a one year low of $78.90 and a one year high of $130.20. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. The company has a market cap of $61.35 billion, a P/E ratio of 40.93, a P/E/G ratio of 3.18 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.08. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. During the same period in the prior year, the company earned $0.77 EPS. The firm’s revenue was up 9.3% compared to the same quarter last year. As a group, sell-side analysts predict that Zoetis Inc will post 3.57 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Tuesday, October 22nd will be paid a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.